Displaying 1 - 12 of 24
Viral Hepatitis
1

GSK: Time to rethink chronic hepatitis B: Quantitative hepatitis B surface antigen today and tomorrow (Complete Session) - EASL Congress 2024

View
Viral Hepatitis
1

GSK: Time to rethink chronic hepatitis B: A roadmap to functional cure (Complete Session) - EASL Congress 2024

View
Viral Hepatitis
5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View
Viral Hepatitis
5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View
Viral Hepatitis
5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View
Viral Hepatitis
5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View
Viral Hepatitis
2

GSK: HBsAg clearance in chronic hepatitis B: How close is it? - ILC 2021

View
Viral Hepatitis
2

GSK: HBsAg clearance in chronic hepatitis B: How close is it? - ILC 2021

View
Viral Hepatitis
6

Gilead Sciences: A new beginning in hepatitis delta - ILC 2021

View
Viral Hepatitis
6

Gilead Sciences: A new beginning in hepatitis delta - ILC 2021

View
Viral Hepatitis
6

Gilead Sciences: A new beginning in hepatitis delta - ILC 2021

View
Viral Hepatitis
6

Gilead Sciences: A new beginning in hepatitis delta - ILC 2021

View
Displaying 1 - 12 of 24